Nuclein

Executive Summary

Nuclein is a San Diego-based diagnostics company that has developed the DASH™ Rapid PCR System, a point-of-care platform capable of delivering lab-quality PCR results in 15 minutes. The system is FDA-cleared and CLIA-waived for a combined SARS-CoV-2 and Influenza A/B test, enabling rapid, decentralized testing for respiratory infections. Founded in 2018, the company targets the growing demand for fast, accurate molecular diagnostics outside traditional laboratories, such as in clinics, urgent care centers, and pharmacies. Its compact, cartridge-based design eliminates the need for cold chain logistics and complex sample preparation, making it suitable for a wide range of healthcare settings. With its initial product already approved, Nuclein is poised to expand its menu with additional respiratory panels and potentially other infectious disease assays. The company's focus on point-of-care PCR places it in a competitive but high-growth segment of the diagnostics market. Key upcoming catalysts include the launch of an RSV test, expansion of commercial partnerships, and potential funding or strategic collaborations to scale manufacturing and sales. If successful, Nuclein could capture significant market share by addressing the need for rapid, reliable testing at the point of care.

Upcoming Catalysts (preview)

• Q3 2026Launch of RSV test on DASH platform75% success
• Q4 2026Major distribution partnership with national pharmacy chain60% success
• Q2 2027Series B funding round to scale production80% success